Regeneron’s Fianlimab Flop Rewrites the LAG-3 Playbook — and Bristol-Myers Just Got Luckier
Regeneron's Phase 3 fianlimab trial misses in first-line melanoma, threatening a key pipeline asset and handing Opdualag a competitive...
Regeneron
Regeneron Priced Otarmeni at Zero — And That’s the Most Expensive Move in Ultra-Rare Disease This Decade
Regeneron's FDA-approved gene therapy Otarmeni targets just 20–50 U.S. births yearly. Its free pricing strategy could cost every rare...